Comintelli improves its rating in major intelligence software review
September 4, 2006Comintelli launches new version 5 of its award-winning software for competitive intellligence
April 19, 2007
Ottawa , Canada – 8 September, 2006
06:30 AM EST
For immediate release.
Comintelli, the leading provider of competitive intelligence software, today announced that Theratechnologies (TSX: TH), a Canadian biopharmaceutical company, has selected and implemented Comintelli Knowledge XChanger (KXC) to power their competitive intelligence system. Being a late-stage bio-tech company, the need for strategic intelligence is fundamental for Theratechnologies and they now have a tool that helps them identify growth opportunities and gives early warning of competitive threats.
The implementation of Comintelli KXC was easy and fast for the IT team at Theratechnologies. They were particularly pleased with the integration with Microsoft Active Directory, which offers users single sign on access to the CI system, relieving them of having to log in separately to Comintelli KXC.
”Theratechnologies has a clear vision of what they want to accomplish with their strategic intelligence work,” said Jesper Martell, CEO of Comintelli. “In combination with our experience from the biotech industry, I believe this helped us speed up the implementation process considerably.”
“Following a thorough analysis of our needs and all CI systems available, we have chosen Comintelli for the versatility of KXC and its capacity to grow with our organization, the flexibility of the IT group to adapt it to our high security standards and the quality of their customer service,” said Lydia Haulbert, Director of Market Research & Strategic Intelligence at Theratechnologies.
Comintelli will demonstrate its CI solutions at the 6 th annual Pharma and Biotech Competitive Intelligence summit which will take place in Princeton , New Jersey on 18-19 September. For more information about this event, please see http://www.srinstitute.com.
About Theratechnologies
Theratechnologies (TSX: TH), is a Canadian biopharmaceutical company that discovers or acquires novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets. The most advanced program is in Phase 3 clinical development in HIV-associated lipodystrophy. The Company also has other promising projects at various stages of development.
About Comintelli
Comintelli is the leading provider of software for competitive intelligence and knowledge management. Comintelli develops, markets and sells the award winning and patented products Knowledge XChanger and Matrix Analyzer. Comintelli Knowledge XChanger is used globally by thousands of users every day. Major reference customers are found in industries such as biotech, pharmaceuticals, healthcare, IT and telecoms. The company was founded in 1999 and has offices in Stockholm , London , New York , and Ottawa .
For more information:
Please visit Customer Case page or www.theratech.com .
E-mail info@Comintelli.com or call +46 8 6637 600 (US/Cananda: 1-800-485-6402)
(Knowledge XChanger is today called Intelligence2day® Enterprise)
